The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States

Addiction

Volumn 96, Issue 9, 2001, Pages 1267-1278

  Barnett, P G ^a   Zaric, G S ^a   Brandeau, M L ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MECHANISM; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RATE; MAINTENANCE THERAPY; OPIATE ADDICTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SURVIVAL RATE; UNITED STATES;

BUPRENORPHINE; COST-BENEFIT ANALYSIS; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 0034840807     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1360-0443.2001.96912676.x     Document Type: Review

References (44)

1. Reduction of AIDS risk among 41 heroin addicted female street prostitutes: Effects of free methadone maintenance
2. Methadone maintenance and the likelihood of risky needle-sharing
3. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users
4. Drug abuse treatment as AIDS prevention
5. Mortality in heroin addiction: Impact of methadone treatment
6. HIV transmission and the cost effectiveness of methadone maintenance
7. U.S. Proposes rules to better treatment with methadone
8. Buprenorphine treatment of opioid dependence: A review
9. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction
10. Use of buprenorphine in the treatment of opioid addiction II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal
11. Clinical pharmacology of buprenorphine: Ceiling effects at high doses
12. Mortality associated with New South Wales methadone programs in 1994: Lives lost and saved
13. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts
14. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence
15. Buprenorphine versus methadone maintenance for opioid dependence
16. A controlled trial of buprenorphine treatment for opioid dependence
17. Buprenorphine vs. Methadone maintenance treatment for concurrent opioid dependence and cocaine abuse
18. Comparison of buprenorphine and methadone in the treatment of opioid dependence
19. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts
20. A multisite efficacy evaluation of a buprenorphine/naloxone product for opiate dependence treatment
21. French general practitioners' attitudes toward maintenance drug abuse treatment with buprenorphine
22. Methadone maintenance and HIV prevention: A cost-effectiveness analysis
23. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence
24. Prevalence of psychopathology in drug-addicted Dutch
25. Current management of infectious complications in the injecting drug user
26. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: A nested case-control study
27. High-risk sexual behaviors of intravenous drug users in- and out-of-treatment: Implications for the spread of HIV infection
28. Utilities and quality-adjusted life years
29. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection
30. Interpretation of cost-effectiveness analyses
31. The cost-effectiveness of preventing AIDS-related opportunistic infections
32. The cost-effectiveness of preventing cytomegalovirus disease in AIDS patients
33. Health-related quality of life measurement for evaluation research and policy analysis
34. Cost-effectiveness league tables: More harm than good?
35. Some guidelines on the use of cost effectiveness league tables
36. Cocaine use and risky injection and sexual behaviors
37. Social network characteristics and injecting HIV-risk behaviors among street injection drug users
38. High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors